Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORA | P35398 | 6/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 11/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | RORB | Q92753 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8246618 | 0.82 | CA12 (0.49) | SMN1; SMN2RORCCA12CA14CA1 | |
| SCHEMBL8237935 | 0.80 | CA12 (0.50) | SMN1; SMN2CA12CA14CA1CA7 | |
| SCHEMBL23502328 | 0.80 | SMN1; SMN2 (0.64) | RORASMN1; SMN2RORC | |
| SCHEMBL2944332 | 0.80 | NR1H3 (0.66) | RORANR1H3SMN1; SMN2RORCNR1H2 | |
| SCHEMBL18519525 | 0.79 | CA12 (0.49) | SMN1; SMN2CA12CA14CA1CA7 | |
| SCHEMBL12107288 | 0.79 | CA12 (0.49) | CA12CA14CA1CA7CA2 | |
| SCHEMBL16038956 | 0.79 | CA12 (0.62) | CA12CA14CA1CA7CA2 | |
| SCHEMBL22638581 | 0.78 | CA12 (0.51) | NR1H4CA12CA14CA1CA7 | |
| SCHEMBL19808335 | 0.77 | CA1 (0.47) | CA12CA14CA1CA7CA2 | |
| SCHEMBL24667477 | 0.77 | HPGD (0.54) | SMN1; SMN2CA12CA14CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | ME2, PC, ACACA | RORA 2055/4885NR1H3 1227/4885SMN1; SMN2 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.